BTKIBaltic Terminal Kiel International (Germany)
References in periodicals archive ?
Patients had received an average of 4 lines of prior therapy, and all patients had progressed on prior BTKi therapy.
The poster, titled Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Brutons Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Lymphoid Malignancy Patients with Prior BTKi Therapy, Abstract No.